Ophthalmology

Adding vitrectomy with ILM peeling to a treat-and-extend anti-VEGF therapy showed no benefit on visual or anatomic outcomes in DME treatment.

A deep-learning model displayed a strong performance in accurately identifying myopia, strabismus, and ptosis using smartphone images.

Ocugen will initiate expanded access to OCU400 gene therapy in adults with retinitis pigmentosa prior to BLA approval.

Postprocedure endophthalmitis substantially decreased between 2000 and 2002, with prompt vitrectomy used less frequently as first-line treatment.

Our July 2024 month in review in ophthalmology includes the latest updates to the ophthalmological pipeline and a trio of studies on the treatment landscape for retinal diseases.

Patients with hemoglobin SS sickle cell disease type may experience a significantly elevated risk of retinal vascular occlusion.

A first-time comparison in US patients displays the protective association of DOACs over warfarin use on RVO and intraocular bleeding risk.

A teleretinal screening program improved the awareness of sickle cell retinopathy and motivated patients to visit an eye care provider.

Older patient age was linked to suboptimal anti-VEGF response for diabetic macular edema in DRCR clinical trials.

Geographic atrophy in eyes with dry AMD and macular atrophy in fellow eyes with neovascular AMD demonstrate similar growth rates.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key interviews from the American Society of Retina Specialists (ASRS) 42nd Annual Meeting.

Pre-dose IOP outcomes in eyes with DME receiving aflibercept 8 mg or 2 mg were comparable through Week 48 of the Phase 2/3 PHOTON trial.

A post hoc analysis of PHOTON showed the utility of aflibercept 8 mg in patients with DME, irrespective of baseline visual acuity.

A recap of the 5 most popular topics related to gene therapy in ophthalmology coming from the 42nd American Society of Retina Specialists meeting.

Hesitancy with anti-VEGF biosimilars was identified in a survey among both ophthalmologists and patients with nAMD in Canada.

Across 40 clinical scenarios, ChatGPT did not provide a comprehensive response in 50% of clinical questions with nearly 30% hallucinated sources.

Patient factors trended towards an association with a higher risk of proliferative sickle cell retinopathy but did not reach statistical significance.

Intravitreal dosing of sozinibercept up to 2 mg in combination with ranibizumab or aflibercept was well tolerated and supported ≥Q8W dosing intervals.

A database analysis linked semaglutide use to notable reductions in the rates of diabetic macular edema and vitreous hemorrhage in diabetic retinopathy.

Presented at ASRS 2024, late-breaking RHONE-X data shows more than 90% of patients experienced the absence of DME after four years of faricimab.

The FDA accepted Genentech’s supplemental BLA for Susvimo, based on the one-year results from the Phase III Pagoda and Pavilion studies.

Eyes with GA that developed MNV in the GATHER trials experienced a slower growth rate with avaincaptad pegol than with sham treatment.

Patients treated with PDS with ranibizumab refilled every nine months maintained vision improvements and experienced consistent safety over two years.

New research presented at ASRS 2024 links maternal asthma to a higher risk of advanced retinopathy of prematurity.

New data from the TEASE-3 trial presented at the ASRS meeting shows gildeuretinol acetate may blunt disease progression in early-stage Stargardt disease patients.

Over 2 years, the Port Delivery System demonstrated continued efficacy with fixed refill-exchange procedures every 24 weeks in the Phase 3 Pagoda trial.

Interim results from the PRISM population extension cohort found that 4D-150 was well tolerated and reduced the mean annualized anti-VEGF injection rate.

At 24 weeks, the oral therapy was well-tolerated and the safety profile remained in line with previous brepocitinib studies and the pharmacological class.

One-year 1/2 data examines the safety and efficacy of OCU400 gene therapy for the treatment of retinitis pigmentosa.

New data from RHONE-X at ASRS suggest over 90% of DME patients treated with faricimab (Vabysmo) were DME-free at 4 years, with nearly 80% on 3-4 month dosing intervals.